KOPRAN vs MANKIND: Stock Comparison
MANKIND PHARMA is the larger company by market capitalisation. KOPRAN shows a lower P/E, a higher dividend yield and lower leverage, while MANKIND PHARMA shows a higher ROE, faster revenue growth and a higher ROCE. These are relative readings on individual metrics — weigh valuation against growth, margins, leverage and capital efficiency rather than treating any single number as decisive.
Metric snapshot
KOPRAN leads 5; MANKIND leads 8 of 13
Interactive comparison
Compare the numbers that shape the decision
Every row uses its own scale. Switch lenses to compare like with like.
Valuation lens
What price are you paying?
✓ marks the usual favourable reading; it is not a recommendation.
Key Differences
Each difference is a single, relative reading — StockeZee does not name an overall winner.
Profile
| Metric | KOPRAN | MANKIND |
|---|---|---|
| Sector | Healthcare | Healthcare |
| Industry | Pharmaceuticals | Pharmaceuticals |
Price
| Metric | KOPRAN | MANKIND |
|---|---|---|
| Live Price | ₹232.54 | ₹2,327.9 |
| Day Change | 0.13% | -1.73% |
| Volume | 6.61 L | 1.22 L |
| 52-Week High | ₹239.6 | ₹2,674 |
| 52-Week Low | ₹107 | ₹1,909.7 |
| Distance from 52W High | -2.95% | -12.94% |
Valuation
| Metric | KOPRAN | MANKIND |
|---|---|---|
| Market Cap | ₹1,120 Cr | ₹96,168 Cr |
| P/E Ratio | 37.34x | 47.96x |
| P/B Ratio | 1.76x | 6.03x |
| EPS | ₹1.39 | ₹13.52 |
| Book Value | ₹109.82 | ₹401 |
| Dividend Yield | 2.76% | 0% |
Growth
| Metric | KOPRAN | MANKIND |
|---|---|---|
| Revenue Growth (TTM YoY) | -3.66% | 11.8% |
| EPS Growth (TTM YoY) | -71.88% | 31.7% |
| Qtr Sales Growth | -59.25% | -26.46% |
| Qtr Profit Growth | 0.33% | -2.72% |
Profitability & Leverage
| Metric | KOPRAN | MANKIND |
|---|---|---|
| ROE | 4.85% | 11.7% |
| ROCE | 4.89% | 11.17% |
| Net Margin | 3.78% | 13.34% |
| Operating Margin | 6.58% | 20.73% |
| Debt to Equity | 0.29x | 0.38x |
Shareholding
As of Jun 2026 • change vs previous quarter| Metric | KOPRAN | MANKIND |
|---|---|---|
| Promoter Holding | 44.42% | 72.63%▼ 0.03 pp |
| FII Holding | 0.51%▼ 0.06 pp | 9.45%▼ 0.79 pp |
| DII Holding | 0% | 15.39%▲ 0.93 pp |
| Public Holding | 55.06%▲ 0.06 pp | 2.53%▼ 0.11 pp |
How to Read This Comparison
Valuation ratios (P/E, P/B) use the latest consolidated figures where available; growth numbers compare against the same period last year; shareholding percentages come from the most recent quarterly filings, with the change shown against the prior quarter. A "more favourable" highlight is relative between these two companies only — it is not a rating, a recommendation, or a comparison against the wider sector. Rows with no reported data for either company are hidden rather than shown empty.
Deep-dive each company on its stock page for quarterly results, technicals, filings and the full peer set: KOPRAN and MANKIND PHARMA.
Related Comparisons
Data source: NSE and company filings via StockeZee. This comparison is informational — it is not investment advice, and StockeZee is not a SEBI-registered investment adviser.